DermPathe Pharmaceuticals

Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.

Pharmaron is a contract research organization (CRO).

Services:
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services

www.pharmaron.com

CRO - Contract Research Organization
Library Synthesis
CADD
Bioorganic Chemistry
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
ChemInformatics
in vitro Biology
in vitro Screening
Structural Biology
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
Biomarkers
in vitro ADME
in vivo PK
PKPD
QA
Regulatory Affairs
Discovery Biologics
Process Chemistry
API Manufacturing
Material Science
Formulation Development
Drug Product Manufacturing
Toxicology
Safety Pharmacology
Genetic Toxicology
DART
Pathology
Immunotoxicity
Bioanalytical
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
QWBA
mARG
Clinical AME
Mass Balance
Metabolite Profiling
Microdosing Phase 0
Absolute Bioavailability
DDI
First-in-Human (FIH)
Thorough QT(TQT)
Ethnobridging

Altogen Labs is a biology CRO company providing GLP preclinical research services, tox studies for IND applications, RNAi and gene silencing services, xenograft testing services (100+ tumorigenic cell lines), in vivo siRNA delivery and biodistribution, development of stable cell lines, and many more.

Altogen Labs is a GLP compliant laboratory that provides preclinical research and biotechnology contract research services (CRO) to pharma, biotechnology companies, universities, and cancer research centers worldwide. Our services include pharmacology and toxicology assays (IC50), cell banking, generation of stable cell lines, RNAi gene silencing and other in vitro services. Altogen Labs provides following in vivo services for efficacy studies in the drug discovery phase: rodent xenograft models, teratoma formation and analysis services, cancer disease animal models, in vivo siRNA delivery and tissue targeting, pharmacokinetics (PK) and pharmacodynamics (PD) services, immune response and biomarker analysis.

Altogen Labs recently developed an `active bioremediation`​ process based on an approach using the most potent oil-degrading bacteria found at multiple oil spill sites in Texas. This technology allows remediation of large amounts of hydrocarbon-contaminated liquids or soil. The genomes of both microorganisms were recently sequenced, which revealed that both strains were previously unreported in the literature. Altogen Labs filed bioremeddiation patent application in 6/2012.

MedChem Partners is a medicinal chemistry CRO founded in 2006 by Tsvetelina Lazarova and Steven Riesinger. The company is focused on using the extensive experience in early stage company formation and drug discovery to effectively advance small molecule candidates for clients by working closely with the client’s biology and/or chemistry resources. Our experts have extensive experience in moving projects from inception through discovery and into development up to IND enabling toxicology.

At MedChem Partners, we are experts at using synthetic and medicinal chemistry to develop small molecule therapeutics. Unlike large one-stop shops that spread their attention over a variety of tasks, we focus on what we know best. Our expertise is in formulating and implementing a plan to find and optimize small molecules which interact with novel or known biological targets. Whether you already have potential molecules in mind, or have just discovered a novel target, we can develop a plan to find and optimize compounds with therapeutic potential. Since drug discovery is a multidisciplinary endeavor, we have foraged close contacts with a variety of other service providers to augment our expertise in certain areas. Since each company is focused on what it does best, this approach allows us to tap into the best talent in each area. Through out network we have access to in vitro and in vivo testing, in vitro and in vivo pharmacokinetics, computer modeling and in silico prediction, formulation, scale-up and manufacturing, toxicology and regulatory filing, x-ray crystallography, intellectual property and patenting, and consultants in clinical, regulatory, manufacturing, pharmacology, and toxicology.

Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately women-owned, pre-clinical accelerator based in Ann Arbor, Michigan focused on building companies that develop infectious disease therapeutics. A key aspect of our strategy is our Technology Accelerator, an ongoing collaborative process that lends our expertise and capabilities to entrepreneurs seeking to obtain the data and non-dilutive funding necessary to develop and/or commercialize their inventions. One focus is improving existing drug products by applying our versatile prodrug platform technologies to optimize therapy regimen for treating infectious diseases. Potential target indications include: influenza, HSV, VZV, CMV, EBV, poxvirus, HPV, Adenovirus, and RNA viruses.

We currently employ ten full-time employees and a number of drug development consultants and generate annual revenues of approximately $2M from royalties and grants. Our team has broad experience in chemistry, molecular biology, biochemistry, analytical chemistry, in vivo animal model, PK/ADME, toxicology and formulation. Our research is conducted in a 7,200 sq. ft. facility of which 5,000 sq. ft. is wet lab space, with on-site analytical chemistry, formulation, cell culture equipment and in vivo testing capabilities.

CustomArray, Inc. is a company dedicated to providing products and services to the "Omics" marketplace.

CustomArray can provide instruments such as the B3™ Synthesizer that uses semiconductor arrays to rapidly synthesize DNA arrays “on chip”. Arrays can be synthesized automatically on the instrument using either the 4x2k™, 12k™, or 90k™ array chips. In situ synthesis on up to 32 arrays (for 4x2k format) or 8 arrays (for other formats) can be performed in under 24 hours. We can also provide pre-made arrays ready for your experiment, and arrays can be read either using standard fluorescence chip readers (one-color or two-color readouts) or can be read using electrochemical detection on our ElectraSense reader. CustomArray also offers extensive services using our platforms to measure gene expression, to measure microRNA expression, to identify aptamer sequences (DNA sequences that bind with high affinity to customer-provided proteins), to identify potent siRNA sequences against select targets in vitro and validate the function of these targets both in vitro and in vivo, to provide large pools of oligos for specific applications such as sequencing, as well as other services.

More information on products and services is in the "products" section of the website. We look forward to continuing to supply essential products to previous customers and welcome new customers to explore the advantages of our technologies and services.